Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0016719 (
Friedreich's ataxia
)
2,098
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Friedreich's ataxia
(
FRDA
) is an autosomal recessive neurodegenerative disorder caused by a GAA repeat expansion mutation within intron 1 of the FXN gene, resulting in reduced levels of frataxin protein. We have previously reported the generation of human FXN yeast artificial chromosome (YAC) transgenic
FRDA
mouse models containing 90-190 GAA repeats, but the presence of multiple GAA repeats within these mice is considered suboptimal. We now describe the cellular, molecular and behavioural characterisation of a newly developed YAC transgenic
FRDA
mouse model, designated YG8sR, which we have shown by DNA sequencing to contain a single pure GAA repeat expansion. The founder YG8sR mouse contained 120 GAA repeats but, due to intergenerational expansion, we have now established a colony of YG8sR mice that contain ~200 GAA repeats. We show that YG8sR mice have a single copy of the FXN transgene, which is integrated at a single site as confirmed by fluorescence in situ hybridisation (FISH) analysis of metaphase and interphase chromosomes. We have identified significant behavioural deficits, together with a degree of glucose intolerance and insulin hypersensitivity, in YG8sR
FRDA
mice compared with control Y47R and wild-type (WT) mice. We have also detected increased somatic GAA repeat instability in the brain and cerebellum of YG8sR mice, together with significantly reduced expression of FXN,
FAST-1
and frataxin, and reduced aconitase activity, compared with Y47R mice. Furthermore, we have confirmed the presence of pathological vacuoles within neurons of the dorsal root ganglia (DRG) of YG8sR mice. These novel GAA-repeat-expansion-based YAC transgenic
FRDA
mice, which exhibit progressive
FRDA
-like pathology, represent an excellent model for the investigation of
FRDA
disease mechanisms and therapy.
...
PMID:A novel GAA-repeat-expansion-based mouse model of Friedreich's ataxia. 2568 19
Friedreich ataxia
(
FRDA
) is a multisystem genetic disorder caused by GAA repeat expansion mutations within the FXN gene, resulting in heterochromatin formation and deficiency of frataxin protein. Elevated levels of the FXN antisense transcript (
FAST-1
) have previously been detected in
FRDA
. To investigate the effects of
FAST-1
on the FXN gene expression, we first stably overexpressed
FAST-1
in non-
FRDA
cell lines and then we knocked down
FAST-1
in
FRDA
fibroblast cells. We observed decreased FXN expression in each
FAST-1
overexpressing cell type compared to control cells. We also found that
FAST-1
overexpression is associated with both CCCTC-Binding Factor (CTCF) depletion and heterochromatin formation at the 5'UTR of the FXN gene. We further showed that knocking down
FAST-1
in
FRDA
fibroblast cells significantly increased FXN expression. Our results indicate that
FAST-1
can act in trans in a similar manner to the cis-acting
FAST-1
overexpression that has previously been identified in
FRDA
fibroblasts. The effects of stably transfected
FAST-1
expression on CTCF occupancy and heterochromatin formation at the FXN locus suggest a direct role for
FAST-1
in the
FRDA
molecular disease mechanism. Our findings also support the hypothesis that inhibition of
FAST-1
may be a potential approach for
FRDA
therapy.
...
PMID:FAST-1 antisense RNA epigenetically alters FXN expression. 3046 93